EUVIMEDEUVIMED entdecken
Crossref

Dual-adjuvanted GPC3 mRNA vaccine delivered by lipid nanoparticles for hepatocellular carcinoma immunotherapy

Yuhao Jiang, Jianhong Luo, Chao Liu, Wenliang Xue, Jinyu Liu, Muyaxin Wang, Shasha Shi, Xudong Yin, Xinsong Li

Journal of Controlled Release · 2026-07 · 395 · 114992

DOI: 10.1016/j.jconrel.2026.114992 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-07. Verfasst von Yuhao Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China. Hauptthemen laut MEDLINE: Cancer Vaccines, Carcinoma, Hepatocellular, Glypicans, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Key Research and Development Program of Hunan Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glypican-3 (GPC3) is a sought-after immunotherapeutic target for hepatocellular carcinoma (HCC) due to its tumor-specific expression. However, GPC3-derived peptide vaccines suffer from limited epitope coverage and weak immunogenicity. Herein, we developed a dual-adjuvanted GPC3 mRNA vaccine delivered by local-retention lipid nanoparticles (LNPs). Through rational ionizable lipids screening, we engineered L1-based lipid nanoparticles (L1-LNPs) that achieved 4-fold greater local expression than ALC-0315-LNPs with reduced hepatic accumulation. A fusion mRNA construct (HGPC3C) encoding GPC3 flanked by two molecular adjuvants of HSP70 peptide and complement C3d was further designed. Mechanistic analyses suggested that HSP70 was associated with enhanced cellular immune responses, including elevated IFN-γ and IL-12p70, whereas C3d was associated with enhanced humoral immune responses, including increased IL-6 and anti-GPC3 antibody titers, together supporting coordinated activation of both immune arms. In prophylactic models, L1-LNPs/HGPC3C mRNA achieved 80.4% tumor suppression. In therapeutic settings, L1-LNPs/HGPC3C (59.9%) significantly outperformed ALC-0315-LNPs and non-adjuvanted formulations, validating the coordinated advantages of local delivery and dual-adjuvant design. Its combination with PD-L1 blockade further increased suppression to 78.3%, with enhanced CD8+ T cell infiltration and antibody production. Collectively, these findings establish L1-LNPs/HGPC3C mRNA as a promising immunotherapeutic approach for HCC treatment and its combination with immune checkpoint blockade holds clinical translational potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesCarcinoma, HepatocellularGlypicansLiver NeoplasmsmRNA VaccinesNanoparticlesRNA, MessengerAnimalsFemaleHumansAdjuvants, ImmunologicCell Line, TumorHSP70 Heat-Shock ProteinsImmunotherapyLipidsMice, Inbred C57BLNanovaccinesLiposomes

Stichwörter der Autor:innen

Dual adjuvantGPC3Hepatocellular carcinomaLipid nanoparticlemRNA vaccine

Substanzen

Adjuvants, ImmunologicCancer VaccinesGlypicansGPC3 protein, humanHSP70 Heat-Shock ProteinsLipid NanoparticlesLipidsmRNA VaccinesNanovaccinesRNA, Messenger

Autor:innen und Institutionen

  • School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China.
  • School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China. Electronic address: lixs@seu.edu.cn.

Förderung

  • Key Research and Development Program of Hunan Province of China

Zitieren

APA

Jiang, Y., Luo, J., Liu, C., Xue, W., Liu, J., Wang, M., Shi, S., Yin, X., & Li, X. (2026). Dual-adjuvanted GPC3 mRNA vaccine delivered by lipid nanoparticles for hepatocellular carcinoma immunotherapy. Journal of Controlled Release, 395, 114992. https://doi.org/10.1016/j.jconrel.2026.114992

Vancouver

Jiang Y, Luo J, Liu C, Xue W, Liu J, Wang M, et al. Dual-adjuvanted GPC3 mRNA vaccine delivered by lipid nanoparticles for hepatocellular carcinoma immunotherapy. Journal of Controlled Release. 2026;395:114992. doi:10.1016/j.jconrel.2026.114992

BibTeX
@article{Jiang2026,
  author = {Jiang, Yuhao and Luo, Jianhong and Liu, Chao and Xue, Wenliang and Liu, Jinyu and Wang, Muyaxin and Shi, Shasha and Yin, Xudong and Li, Xinsong},
  title = {Dual-adjuvanted GPC3 mRNA vaccine delivered by lipid nanoparticles for hepatocellular carcinoma immunotherapy},
  journal = {Journal of Controlled Release},
  year = {2026},
  volume = {395},
  pages = {114992},
  doi = {10.1016/j.jconrel.2026.114992}
}
Kostenlos starten →